Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study indicates that progesterone’s anesthetic activity in PR knockout mice is not due to progesterone receptors but is partially mediated by the neurosteroid allopregnanolone through GABAA receptor potentiation.

This study observed that liposomes encapsulating minoxidil and PEP penetrate the skin at a slower rate but may reach deeper layers compared to a foam formulation.

This study found that in patients with female androgenetic alopecia, mesodermal injection of 0.5% minoxidil was more effective in increasing hair density and improving hairline height than topical 2% minoxidil, with comparable safety over 16 weeks.

This study found that 1 mg/day low-dose oral minoxidil significantly increased hair count compared to 0.25 mg/day over 24 weeks in women with female pattern hair loss, though no differences were observed in hair-shedding and quality-of-life scores between the two doses.

This study found that using a stevioside-based microneedle patch significantly increased minoxidil's solubility and skin absorption, promoting hair growth in animal models and achieving 67.5% area coverage by day 35, highlighting the potential of this novel delivery system for androgenetic alopecia treatment.

This source reports that clascoterone cream has been approved in the U.S. for treating acne vulgaris in patients aged 12 and older, suggesting it works by competing with dihydrotestosterone at androgen receptors to mitigate acne's effects.

This study reports that using ascorbic acid or orlistat can significantly inhibit the metabolism of testosterone esters into malodorous metabolites by axillary bacteria, suggesting potential new deodorant applications.

The researchers reported that finasteride prevents further hair loss in males with androgenetic alopecia by promoting hair growth, which helps maintain scalp coverage, but it is not effective for females.

This article discusses a forthcoming advertising campaign for minoxidil, highlighting the need for dermatologists to understand its efficacy, with reports showing it was significantly superior to placebo in promoting hair growth at four months.

This study identified new oxidative derivatives of finasteride, including a newly discovered metabolite, by using the fungus Macrophomina phaseolina.

This study reports that RU 58841-myristate, a new antiandrogen prodrug formulated with solid lipid nanoparticles, shows potential for targeting hair follicles in preclinical laboratory settings.

This article discusses a planned advertising campaign for topical minoxidil as a treatment for male pattern baldness and reports that it was significantly superior to placebo in clinical trials.

This study suggested that moxibustion treatment before or at the early stage of diminished ovarian reserve in rats may improve ovarian function by modulating androgen balance, though its effects differ across intervention timings.

Low-dose oral minoxidil alone is effective for treating hair loss, but combining it with dutasteride or finasteride may offer better results.

This study found that among various treatments for male androgenetic alopecia, dutasteride 0.5 mg/day was the most effective option overall. Additionally, among FDA-approved treatments, topical minoxidil 5% was the most effective topical therapy, and finasteride 1 mg/day was the most effective oral therapy.

Scale created to measure hair loss in men and women; MK-386 reduces acne; Niaspan treats dyslipidemia; minoxidil increases heart rate.

This review discusses emerging therapies for androgenetic alopecia, including topical finasteride, oral minoxidil, and intradermal dutasteride, and reports no clinical results; the authors highlight changes in treatment approaches.

This study observed that patients using a novel topical combination of finasteride and minoxidil for male androgenetic alopecia reported high satisfaction and good tolerance, with few side effects and no need for higher-level care, despite limitations such as retrospective data and no control group.

Minoxidil base is preferred for hair loss treatment, but minoxidil sulfate may be an alternative for unresponsive patients.

Minoxidil and 4-MA can help treat hair loss.

This article reviews updates on 5 alpha-reductase inhibitors for treating male pattern hair loss and presents no new clinical findings; the author aims to enhance understanding of these therapies.

This case series reports the experience of using oral minoxidil at 1.25 mg/day in 32 patients with male androgenetic alopecia, noting both therapeutic effects and potential adverse reactions.

In a cell-free test setting, this study found that a novel saw palmetto extract effectively inhibited the 5α-reductase type II enzyme, showing promising bioactivity comparable to finasteride for promoting prostate health.

Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.

Chitosan-coated nanocapsules improve minoxidil delivery for better hair regrowth.

This study reported that topical 2% minoxidil solution improved hair growth compared to placebo in men with early male-pattern baldness over 24 weeks, with no significant safety issues observed.

This study found that Polygoni multiflori Radix water extracts accelerated hair regrowth and hair follicle development in mice, showing a safer profile compared to minoxidil.

This study found that Monascus cursory extraction reduced baldness, prostate hyperplasia, and tumor incidence in animal models of androgen-related diseases, suggesting it may be a promising new therapeutic candidate.

In this study, intradermal injections of 0.5% minoxidil significantly improved hair growth and volume in women with female androgenetic alopecia compared to a placebo, with a good safety profile reported.